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Abstract
Aptamers are single-chained RNA or DNA oligonucleotides (ODNs) with a three-dimen-
sional conformation that provides the ability to fit their targets with high affinity and 
specificity obtained by a method called SELEX. Cancer immunotherapy has nowadays 
come back to prominence due to its encouraging results in the clinic with monoclonal 
antibodies. Aptamers display some important advantages over antibodies at the time 
of translation into the clinic. They are very suitable for targeting and delivery, reducing 
off-target side effects, and increasing the therapeutic index of a given strategy. Hundreds 
of aptamers have been described for very different purposes within biomedical research. 
Some of the aptamers described recently have been isolated with immunotherapeutic 
applications to overcome current challenges in cancer immunotherapy. To elicit a specific 
antitumor immune response, some of these aptamers are engineered to activate co-stim-
ulatory receptors or blocking immunosuppressive signals. Aptamers would hopefully 
gain an important niche in cancer immunotherapy due to their specific properties.
Keywords: aptamer, oligonucleotide, receptor, cancer, immunotherapy, immune 
system
1. Introduction
Oligonucleotides (ODNs) are short DNA or RNA oligomers presented as single- or double-
stranded molecules containing a specified sequence. This kind of molecules can be generated 
to be used for a large variety of purposes, such as artificial gene synthesis, DNA sequencing, 
library construction, molecular probes, and regulation of gene expression, among others. The 
technical support in terms of detection and analysis that ODNs provide in daily laboratory 
work is not but a small part of their current use. Nowadays, ODN molecules such as small 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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interfering RNAs (siRNAs), short hairpin RNAs (shRNAs), CpGs, and aptamers are being 
currently used as therapeutic agents for the treatment of diseases and malignancies of very 
different nature.
Aptamers are single-stranded DNA or RNA (ssDNA or ssRNA) oligonucleotides; their 
three-dimensional conformation provides them with the capability to fit in their targets with 
high affinity and specificity. The word “aptamer” was coined by Jack Szostak and results 
from the junction of two words, “aptus” which comes from Latin and means “to fit” and 
“meros” which comes from Greek and means “particle.” The first aptamer was isolated 
by Andy Ellington and Jack Szostak in 1990 toward organic dyes and paralleled by Craig 
Tuerk and Larry Gold against the T4-bacteriophage DNA polymerase [1, 2]. Aptamers are 
isolated through a combinatorial chemical method named SELEX, meaning systematic evolu-
tion of ligands by exponential enrichment. The SELEX method (schematically represented 
in Figure 1) is an iterative process that consists in rounds of selection. Each round comprises 
three main steps: “binding,” “partition,” and “amplification” [1, 2]. The first step is called 
“binding” and begins with a complex randomized library of 1012 to 1015 different sequences to 
ensure the majority of potential structures. Each sequence comprises two constant regions at 
 Figure 1. The SELEX procedure. The systematic evolution of ligands by exponential enrichment consists in three main 
steps: binding, partition, and amplification.
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3′ and 5′ ends allowing the primers to anneal flanking a variable region that can vary from 20 
to 100 nucleotides (nt). Throughout this step, the library is mixed with the target of interest to 
allow for some of the sequences to join the target. The following step is known as “partition” 
and consists in separating the target-binding species from non-binders. Finally, the binder 
species are amplified by polymerase chain reaction (PCR) in the “amplification” step to serve 
as library for the next round of selection. It is to note that if the aptamer of interest is an RNA 
aptamer, in vitro transcription shall be performed before starting each round. The SELEX 
process usually takes from 9 to 15 rounds, which implies months of work, but new tools such 
as high-throughput sequencing enable the researchers to identify already enriched sequences 
at early selection stages, thereby reducing the number of rounds and hence the amount of 
work to be done [3, 4]. Since the first aptamers isolated by the conventional selection proce-
dure, the SELEX method has evolved and varied through time with the objective of isolating 
aptamers against targets from every possible nature, including sugars, vitamins, proteins, or 
even small molecules [5, 6]. Some of the variations are CE-SELEX, which comes from capillary 
electrophoretic SELEX [7]; cell-SELEX, in which selection is carried out with cells [8]; toggle-
SELEX, which on the other hand is used to obtain cross-reactive aptamers [4, 9]; and tailored-
SELEX [10], which is used to identify 10-fixed nucleotide aptamers without primer-binding 
sites. Tailored-SELEX was validated when a Spiegelmer against the migraine-associated 
target calcitonin gene-related peptide 1 (alpha-CGRP1) was isolated [10]. Spiegelmers are a 
recently described new class of aptamers, which are “mirror-image” L-conformed enantiomer 
aptamers [11]. Moreover, in vivo SELEX performs the rounds of selection in animals [12], and 
genomic SELEX is otherwise used to achieve what are called genomic aptamers directed to 
bind genomic-encoded functional domains [13].
As mentioned above, aptamers can be isolated against molecule from almost every nature 
with high affinity and specificity which, in the majority of cases, is comparable or even supe-
rior to that of their corresponding monoclonal antibodies (mAbs). Indeed, a DNA aptamer 
against IL-6 that recognizes this interleukin with a dissociation constant (K
d
) of 0.2 nM has 
been recently described [14]. Following this, line aptamers show several advantages over cell-
based products such as antibodies (Abs) or recombinant proteins, as summarized in Table 1. 
Aptamers are smaller than cell-based products, which provide them with an ease to penetrate 
tissues and therefore make them very suitable for targeting. Thanks to their chemical nature 
aptamers can be modified to optimize yield and easily customized to add tailored properties 
to carry cargoes from very diverse nature such as drugs, radioisotopes, proteins, enzymes, 
RNAs, or even nanostructures, greatly favoring their use for delivery [15–17]. Moreover, 
aptamers can be easily multimerized to modulate the immune system [18–22]. Throughout 
the SELEX technique, the process is not interfered with by the toxicity or low immunogenicity 
of specific antigens as might befall, for example, with Abs [22]. Cell-based products such anti-
bodies or recombinant proteins usually show T-cell-dependent immunity, meaning that an 
immune response can be directed against these compounds unlike what happens with short 
ODNs such as aptamers. At the time of translating, the approaches to the clinic aptamers pos-
sess a great advantage over other kinds of molecules since they inherently present an antidote 
[23, 24]. Aptamers are chemical products that can be synthetically manufactured what facili-
tated their exportation to GMP grade (good manufacturing practices or the practices required 
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to manufacture and sell any pharmaceutical product). This feature privileges aptamers over 
antibodies since regulatory approval processes are tougher on cell-based products due to 
their high complexity and cost of manufacturing.
Aptamers present one disadvantage over other agents currently used in translational medi-
cine—their low plasma stability. Nonetheless, their half-life in plasma can be significantly 
enhanced by using different approaches, such as selective substitution of HO residues by 
O-methyl or F analogs at the 2′ position of the pyrimidine interactions, thus increasing their 
resistance to RNA-degrading enzymes [5, 25]. Aptamers can be conjugated to cholesterol 
to enhance their half-life at the same time that improves their biological activity [26–28]. 
Another alternative clinically compatible carrier is polyethylene glycol (PEG) [29], which pre-
vents its renal exclusion [5]. PEG conjugation highly increases aptamer survival as exempli-
fied by a PEGylated anti-MUC1 aptamer-doxorubicin conjugate [30]. The PEGylated form of 
this MUC1-doxorubicin conjugate increased its survival rate to a maximum of sixfold [30]. 
Furthermore, the addition of nonnatural analogous bases can widen the aptamer-target inter-
actions [5, 25]. This is the case of slow off-rate modified aptamers (SOMAmers), in which 
aromatic hydrophobic modified nucleotides such as benzyl-dU (Bn-dU) and naphthyl-dU 
(Nap-dU) are added [31]. Slow off-rate modified aptamers (SOMAmers) show protein-like 
modified side chains. These substitutions advantage them over conventional aptamers in 
decreasing the number of exposed polar groups and augmenting their affinity [31].
A tremendous amount of new selected aptamers has been published since the first aptamer 
isolated in the early 1990s [5, 32, 33]. Some of them are currently undergoing clinical trials for 
the treatment of several diseases, such as macular edema and age-related macular degenera-
tion as in the case of the antiplatelet-derived growth factor (PDGF) and the anticomplement 
component (C5) RNA aptamers [34, 35]. Some RNA aptamers including the antifactor IXa of 
coagulation and the anti-A1 domain for activated von Willebrand factor (vWf) are directed 
Feature Aptamer Cell-based product Advantage
Nature Chemically synthesized Produced by cells Easy to multimerize for 
activation of immune 
receptors




Do not trigger immune 
response against them
Size Small (5–90 KDa) Big (50–200 KDa) Easy tissue penetrating,  
very suitable for targeting
Customization Easy procedure Requires specific skills Tailored properties easy 
to add, very suitable for 
delivery
Antidote Yes No Possibility of reversion any 
undesired effect
GMP grade Lower cost of  
manufacturing
Higher complexity and  
cost of manufacturing
Easier regulatory approval 
process
Table 1. Advantages of aptamers over cell-based products.
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to control hemostasis [35–37]. For the treatment of diabetes mellitus, one Spiegelmer is being 
used to target the monocyte chemoattractant protein 1 (MCP-1 also called CCL2) [35]. The 
two most advanced aptamers for cancer treatment are the anti-nucleolin aptamer AS1411 and 
the anti-stroma cell-derived factor-1 (SDF-1 also called CXCL12) NOX-A12 [35]. Among every 
aptamer tested in clinical trials, the first in class was the anti-VEGF RNA aptamer approved 
in 2004 by the Food and Drug Administration (FDA) which is used for the treatment of age-
related macular degeneration and is called MACUGEN.
2. Aptamers in cancer immunotherapy
The cancer burden around the world is extremely growing, to the extent that estimates calculate 
21 million new cancer cases and 13 million cancer deaths from now until 2030 [38]. There exist 
nowadays three main strategies to tackle cancer, namely, chemotherapy, radiotherapy, and sur-
gery in cases of resettable tumors. The elevated relapsing rates and the high toxicity associated 
with current treatments due to their lack of specificity usually make these conventional treat-
ments not powerful enough in many kinds of tumors. Surgery has the inherent problem of not 
removing every single malignant cell, causing tumor relapses in the majority of cases. On the 
other hand, radiotherapy and chemotherapy often show serious side effects, which is not only 
very harmful but also very uncomfortable for the patient. Immunotherapy is now given promi-
nence thanks to the encouraging results obtained in some clinical trials over the last few years 
[39] and the use as monotherapy or in combination of several FDA-approved immune-check-
point blocking Abs such as ipilimumab, nivolumab, or pembrolizumab [40–46]. Nonetheless, 
due to the severe toxicity associated with the use of agonistic mAbs such 4-1BB Ab or super ago-
nistic CD28 Ab (TGN1412) causing hepatic toxicity and cytokine storm, respectively [47–50], 
new immunomodulatory ligands with lower associated side effects are strongly needed.
As mentioned above, aptamers have been used in different research fields such as meta-
bolic and cardiovascular diseases or cancer [5]. Among the number of aptamers used in 
cancer research, some of them have been used to treat cancer within an immunotherapeutic 
context [51]. This chapter will be focused on aptamers used to date for cancer immunother-
apy, which in turn will be subdivided in four main parts: (I) aptamers developed to block 
immunosuppressive signals, (II) agonistic aptamers directed to trigger activating signals, 
(III) bi-specific aptamers to target the immune response to the tumor site, and (IV) aptamer-
based approaches to enhance tumor immunogenicity.
2.1. Aptamers developed to block immunosuppressive signals
In order to find the first aptamer developed with immunotherapeutic intention, we must go 
back to 2003. It was then when a CTLA-4 RNA aptamer was isolated and multimerized to block 
CTLA-4 signaling [18]. Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a member of the immuno-
globulin superfamily expressed by activated T cells, and its engagement with its natural ligand 
B7 (B7.1=CD80 and B7.2=CD86) leads to T-cell exhaustion [52]. The work published by Gilboa’s 
group laid down the foundations for aptamers as new immunotherapeutic agents. In this work, 
the multimerized blocking anti-CTLA-4 RNA aptamer showed to bind its target with high affin-
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ity and inhibited CTLA-4 action in vitro. This tetrameric form (schematically represented in 
Figure 2a) enhanced its in vitro and in vivo effects similar indeed to that of the mAb [18].
Programmed cell death protein 1 (PD-1) is a protein expressed in several cell types. It is 
expressed on the surface of CD8+ T lymphocytes especially in tumor-infiltrating lymphocytes 
(TILs). Its engagement with its ligand PDL-1 expressed on tumor cells induces T-cell exhaus-
tion leading to their dysfunction and therefore tumor progression [53]. An anti-PD-1 DNA 
aptamer (represented in Figure 2b) has been published, which is able to block the PD-1-PDL-1 
axis, thereby decreasing tumor burden and increasing survival in murine tumor models [54].
TIM3 is another T-cell exhaustion maker expressed in CD4+ interferon-γ expressing cells and 
cytotoxic CD8+ T lymphocytes [55]. It is usually expressed on T lymphocytes together with 
PD-1 [55]. Moreover, the upregulation of TIM3 on a subpopulation of infiltrating Tregs has 
been correlated with bad prognosis in patients [56]. Our group has recently described a TIM3 
RNA aptamer with antagonistic capacity [57]. This aptamer (represented in Figure 2c) was 
able to counteract TIM3 inhibitory signal on T lymphocytes in vitro and reduce tumor burden 
in a mouse colorectal tumor model in combination with PDL-1 blockade [57] Moreover, we 
have published at the present time a work that describes the use of in silico and docking stud-
ies to predict the mode of action and potential binding site of novel and the already published 
murine TIM3 RNA aptamer [58].
We have recently selected a murine CD40 RNA aptamer with high affinity for its target (rep-
resented in Figure 2d). Since CD40 is expressed in several B-cell malignancies, we used it 
 Figure 2. Antagonistic aptamers. (a) CTLA-4, (b) PD-1, (c) TIM3, (d) CD40, (e) CD28, (f) BAFF-R, (g) IL-10R, and (h) 
IL-6 and IL-6R.
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to block the CD40 receptor in vitro and in vivo. The experiments resulted in tumor growth 
reduction as we increased mice survival by 30% [21]. We had previously described a CD28 
antagonistic RNA aptamers which in its monomeric form was able to compete for CD28 
ligand B7 and to revert in vitro the co-stimulation induced by B7 in CD4+ T lymphocytes (rep-
resented in Figure 2e) [20]. This antagonistic aptamer could serve as immunosuppressant in 
several autoimmune diseases or transplants. For example, in the host-versus-donor immune 
responses triggered upon transplant engraftment, drug administration is needed to suppress 
the acute response. Thus, the use of this antagonistic CD28 aptamer might serve as suppressor 
of the T-cell-guided immune responses against the graft, easing donor engraftment.
The B-cell-activating factor (BAFF) is produced by dendritic cells, monocytes, macrophages, 
and B cells [59]. The engagement with its receptor has been described to induce B-cell pro-
liferation and survival, and its overexpression has been identified in different B-cell malig-
nancies [60–64]. Aptamers that block BAFF-BAFF-R axis have been selected (represented in 
figure 2f). These aptamers were able to block BAFF-dependent proliferation and survival as 
well as B-cell malignant proliferation [65].
Several aptamers have been described in the last few years aimed to block cytokine signaling. 
IL-10 is an immunosuppressive cytokine that promotes immunomodulatory responses favor-
ing tumor growth. It has been shown to be elevated in plasma of cancer patients, which can be 
used as a prognostic factor in cancer progression [66]. The blockade of its receptor IL-10R has 
been described to inhibit tumor growth in murine tumor models [67, 68]. An IL-10R-blocking 
aptamer has been isolated (represented in figure 2g). This aptamer was optimized by trunca-
tion by removing stearic domains, resulting in an increased affinity for its target [69]. The in 
vivo experiments revealed that it was able in its truncated monomeric form to inhibit tumor 
growth at comparable levels to those of the mAb. It was further tetramerized, and this mul-
timeric form was able to block IL-10-IL-10R axis in vitro [69]. Further, a human and murine 
cross-reactive aptamer against IL-10RA has been recently isolated [4].
A very interesting immunotherapeutic strategy is IL-6-IL-6R axis interruption. IL-6 is a pro-
inflammatory cytokine expressed by B and T cells, monocytes, and fibroblasts [70]. Its pres-
ence within the tumor microenvironment leads to immunoregulatory responses favoring 
tumor growth. Two SOMAmers (represented in Figure 2h) have been selected that bind IL-6 
with high affinity and inhibit IL-6-mediated signaling by blocking its interaction with IL-6R 
[71]. The in vitro experiments revealed a similar effect to that obtained by the correspond-
ing IL-6 mAb tocilizumab [71]. Furthermore, an RNA aptamer toward IL-6 (represented in 
Figure 2h) has been selected which showed no blocking activity but was able to effectively 
deliver cargoes to IL-6 expressing cells [14].
Aptamers toward other cytokines, such as IL-4R or tumor necrosis factor alpha (TNF-α), have 
been selected. A human and murine RNA cross-reactive aptamer was isolated toward IL-4R 
able to induce apoptosis in myeloid-derived suppressor cells (MDSCs). The IL-4R-mediated 
signaling in MDSCs and tumor-associated macrophages (TAMs) resulted in an increased 
number of TILs and reduction of tumor burden in a mammary carcinoma tumor model [72]. 
Finally, a TNF-α DNA-blocking aptamer has been isolated that is able to inhibit its activity 
in vitro [73]. These antagonistic and the remaining aptamers used to date in cancer immuno-
therapy are summarized in Table 2.
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 Type Function Target/s Nature Specie/s Treatment/s Reference
T-cell exhaustion 
markers
Antagonists CTLA-4 RNA Murine Melanoma Santulli-Marotto [18]
PD-1 DNA Murine Colon carcinoma Prodeus [54]
TIM3 RNA Murine Colon carcinoma in combination 
with PD-1 blockade
Hervas-Stubbs [57]
Cytokines IL-10R RNA Murine Colon carcinoma Vicari [68]
RNA Human and murine Not described (*) Levay [4]
IL-6 DNA Human Glioma and hepatoma (in vitro) Gupta [14]
IL-6R RNA Human Not described (*) Scheller [70]
IL-4R RNA Human and murine Mammary carcinoma Meyer [71]
TNF-α DNA Human Prevention of TNF-α-induced 
apoptosis (in vitro)
Roth [72]
Immune receptors CD28 RNA Murine Reversion of CD4 T-cell 
proliferation (in vitro)
Pastor [20]
CD40 RNA Murine B-cell lymphoma Soldevilla [21]
BAFF-R RNA Human Mantle cell lymphoma Kern [64]
Agonists CD28 RNA Murine B-cell lymphoma Pastor [20]
4-1BB RNA Murine Mastocytoma McNamara [19]
RNA Human and murine Not described (*) Levay [4]
OX-40 RNA Human CD4 proliferation (in vitro) Vinay [74]
RNA Murine Melanoma Dollins [75]
CD40 RNA Murine Aplasia recovery Soldevilla [21]
Immunotherapy - Myths, Reality, Ideas, Future
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4-1BB-PSMA RNA-RNA Murine Colon carcinoma Niu [76]
4-1BB-VEGF RNA-RNA Murine Breast carcinoma Pastor [77]
CD28-MRP1 RNA-RNA Murine Chemotherapy-resistant  
melanoma
Gilboa [78]








PSMA-NMD RNA-siRNA Murine Colon carcinoma Pastor [20]
CD40-NMD RNA-shRNA Murine B-cell lymphoma Soldevilla [21]
Increase tumor 
immunogenicity
CTLA-4-STAT-3 RNA-siRNA Murine T-cell lymphoma Kortylewski [80]
4-1BB-mTORC1 RNA-siRNA Murine Melanoma Herrmann [81]
CD28-FOXP3 RNA-peptide Murine Colon carcinoma Casares [82]
DEC205 RNA Murine Melanoma Berezhnoy [3]
Aptamers are divided into categories depending on type and function. Types: T-cell exhaustion markers, cytokines, immune receptors, bi-specific immune receptor-tumor 
marker, increase tumor antigenicity, and increase of tumor immunogenicity. Functions: antagonists, agonists, tumor-targeted co-stimulation, tumor-targeted ADCC, and 
immunomodulating aptamer-based approaches.
Are not described as antagonists.
Table 2. Summary of aptamers used in cancer immunotherapy.
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2.2. Agonistic aptamers directed to trigger activating signals
T lymphocytes need at least two signals to be properly activated. The first one comes from the 
engagement of major histocompatibility complex (MHC) class I in the case of CD8+ and MHC 
class II in CD4+ cells with the T-cell receptor (TCR) along with CD3. The second signal, well 
known as co-stimulatory signal, comes mainly from the engagement of CD28 expressed on 
the surface of T lymphocytes and its ligand B7 expressed on antigen-presenting cells (APCs). 
Within the tumor microenvironment, lack of co-stimulatory ligands leads to T-cell exhaus-
tion, what turns them into anergic cells unable to trigger an immune response. Thus, the 
search for agonistic agent has always been of great interest in cancer immunotherapy. The 
first agonistic aptamer was not described until 2008. It was isolated by conventional SELEX 
toward murine 4-1BB, which is one of the major co-stimulatory receptors expressed in T lym-
phocytes. Its ligand 4-1BBL is expressed on the surface of APCs, and their engagement leads 
to T-cell proliferation [74, 83]. This aptamer was dimerized with the intention of displaying 
agonistic functions. To that end the agonistic aptamer was generated by adding a comple-
mentary 21 nt length to the 3′ end of each monomer using polymerase chain reaction (PCR). 
After in vitro transcription, monomers were hybridized by pair-wise fashion generating a 
dimer with a double-stranded linker, which provides a more rigid structure and mirrors the 
average distance of the two Fv of an IgG (represented on Figure 3a). The use of this 4-1BB 
agonistic RNA aptamer in murine tumor models resulted in inhibition of tumor growth [19]. 
This work strengthened the idea of using aptamers as novel agents for cancer immunother-
apy. Moreover, a human and murine cross-reactive aptamer has been recently published 
[4]. In this work, they describe a parallel both human- and murine-specific target selection 
against IL-10RA and 4-1BB followed by identification of common sequences by HTS. This is 
a “toggle-type” SELEX, which shows a very feasible manner to isolate cross-reactive species 
aptamers [4].
CD28 is one of the main co-stimulatory receptors with a very important role in immuno-
therapy. Our research team has generated multimerized CD28 agonistic RNA aptamers able 
to provide proper CD28 what lead CD4+ and CD8+ proliferation in vitro [20]. Two different 
dimeric structures were generated to evaluate their effect on T-cell co-stimulation and there-
fore optimize the strategy. The first dimer was generated as previously described [19] by 
pair-wise annealing fashion. However, the dimeric structure generated by in vitro transcrib-
ing two contiguous monomer units exerted in this case the highest co-stimulatory capacity in 
CD4+ and CD8+ T lymphocytes [20]. This dimer provides a shorter linker reducing the dis-
tance to the minimum and a more flexible structure (represented in Figure 3b). This agonistic 
CD28 aptamer was able to induce both cellular and humoral response in mice in a context of 
idiotypic vaccination. The use of this agonistic aptamer as adjuvant in an already established 
idiotypic vaccination protocol to treat B-cell lymphoma resulted in decreased tumor growth 
and increased survival rate. This aptamer showed a similar effect to that of the mAb [20].
OX-40 is another co-stimulatory receptor upregulated on the surface of CD4+ T cells upon 
activation, and the engagement with its natural ligand OX-40L expressed on APCs promotes 
T-cell proliferation, increased cytokine release, and long-term survival [75]. An RNA aptamer 
toward murine OX-40 was isolated and engineered to exert agonistic functions (represented 
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in Figure 3c) [75]. It was generated as a two-copy scaffold with 18 nt length polycarbon 
units between the two 3′ aptamer end of the complementary sequences that will anneal by 
pair-wise fashion [75, 84]. Further, a human OX-40 aptamer has been described which in its 
dimeric form provided a co-stimulatory effect as demonstrated by cellular proliferation and 
increased INF-γ production [84].
CD40 is a receptor expressed on the surface of APCs, and its ligand is expressed on T lym-
phocytes. Their engagement promotes clonal expansion, isotype switching, maturation, pro-
liferation, generation of plasma cells in the case of B cells, and increased antigen presentation 
on dendritic cells [85, 86]. We have recently published two different agonistic CD40 RNA 
aptamer-based constructs able to recover bone marrow aplasia while increasing antigen pre-
sentation [21]. As mentioned above, in this work, one of the isolated aptamers acted as an 
antagonist which by simple dimerization was turned into agonist (represented in Figure 3d).
2.3. Bi-specific aptamers to target the immune response to the tumor site
The use of agonistic mAbs has been demonstrated to exert severe toxicities as happened with 
the CD28 superagonistic mAb TGN1412, which resulted in cytokine storm leading a multi-
 Figure 3. Agonistic aptamers. (a) 4-1BB, (b) CD28, (c) OX-40, and (d) CD40.
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organ failure forcing the clinical trial to be concluded [47]. Another example is the elevated 
liver toxicity displayed by the 4-1BB mAb [48]. Moreover, the use of immune-checkpoint 
blockade mAbs raises the major concern of the appearance of several side effects such as hep-
atotoxicity, lymphopenia, and thrombocytopenia [76]. Thus, targeting the immune response 
to the tumor site would reduce the toxicity owed to the off-target effects while increasing the 
therapeutic index. This approach was published for the first time in 2011 by generating the 
first bi-specific aptamer, which consisted of both the PSMA and the agonistic 4-1BB aptamers 
(represented in Figure 4a) [77]. This new approach displayed a more potent antitumor immu-
nity at lower doses than that of the corresponding mAbs or the nontargeted co-stimulation. 
Targeting the immune response to the tumor site is a strategy that requires less amount of 
reagent as demonstrated in this work, which shows that targeted co-stimulation works as 
effectively as 10-fold levels of the corresponding controls [77]. A new bi-specific aptamer has 
been published with the intention of targeting 4-1BB co-stimulation to the vascular endothe-
lial growth factor (VEGF). This new construct consisting of both the VEGF and the agonistic 
4-1BB aptamers (represented in Figure 4b) showed less toxicity than the rest of the controls 
while obtaining the same therapeutic effect [87]. In fact, this therapeutic index widening was 
mirrored in a similar antitumor effect while reducing CD8+ T-cell hyperplasia as well as 
spleen, lymph node, lung, and liver weights [78, 88]. These described works demonstrate the 
feasibility of the strategies based on targeting co-stimulation to the tumor site using aptamers.
We have recently published a bi-specific CD28-MRP1 aptamer to target CD28 co-stimulation to 
cancer stem cells (represented in Figure 4c) [89]. The targeted co-stimulation to cancer stem cells 
which imply chemotherapy resistance would exert a selection pressure on these cells usually 
responsible for tumor metastasis and tumor relapses [79, 90]. We isolated an aptamer that rec-
ognizes multidrug-resistant protein 1 (MRP1) with high affinity, and we used it to generate the 
 Figure 4. Bi-specific aptamers. (a) 4-1BB-PSMA, (b) 4-1BB-VEGF, (c) CD28-MRP1, and (d) CD16α-c-Met.
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CD28-MRP1 bi-specific aptamer together with the already published agonistic CD28 aptamer. 
This bi-specific aptamer was able to target and properly provide co-stimulation signal to MRP1-
overexpressing cells in vitro and in vivo. It was tested in a murine tumor model in the presence 
of a vaccine (Gvax) and a transient inhibitor peptide of FOXP3 resulting in higher T-lymphocyte 
tumor infiltration, slower tumor growth, and longer survival [89]. Further, we developed a new 
vaccination strategy consisting in irradiated MRP1-overexpressing cells coated ex vivo with the 
CD28-MRP1 bi-specific aptamer termed CD28 Aptvax. CD28 Aptvax exerted delay in MRP1-
expressing tumors as well as 50% survival after 50 days of follow-up [89].
Finally, targeted antibody-dependent cell-mediated cytotoxicity (ADCC) can be achieved as 
well. To that purpose, a DNA aptamer against the Fcγ receptor III (CD16α) was developed 
to generate a bi-specific aptamer to target ADCC to c-Met-overexpressing tumor cells (repre-
sented in Figure 4d) [91]. This bi-specific aptamer was tested in both human gastric and lung 
cancer cell lines resulting in specific c-Met-targeted ADCC [91].
2.4. Aptamer-based approaches to enhance tumor immunogenicity
Despite efforts invested in blocking immunosuppressive signals and activating positive signals, 
tumor antigenicity is a challenge that remains mostly unsolved. In 2010, a feasible approach 
was described to increase tumor antigenicity by expressing new tumor antigens. In this work 
published by Pastor et al. [92], new and therefore more potent antigens are expressed by the 
tumor triggering a powerful immune response [92, 93]. This approach was based on generat-
ing an aptamer-based chimera consisting of the PSMA aptamer and an siRNA for one of the 
NMD factors. Nonsense-mediated RNA decay (NMD) is a mechanism that controls abnormal 
transcripts in charge of deleting mRNAs that encode premature termination codons (PTCs). 
This targeted NMD inhibition resulted in triggering an increased tumor antigenicity leading to 
a potent immune response in vivo, thereby reducing tumor growth [92]. Moreover, it has been 
demonstrated that higher lymphocyte infiltration in the tumor is correlated with lower NMD 
expression, as was shown by the inverse correlation between the accumulation of CD3+ and 
the expression of the NMD in colorectal cancer with microsatellite instability [94]. Since tumor 
regression has been demonstrated by the expression of new antigens in the tumor by NMD 
inhibition [92–94], we decided to apply this strategy to B-cell lymphoma. In this work recently 
published by our research team, we generated a chimera with the CD40 agonistic aptamer cou-
pled with an shRNA aimed at inhibiting the NMD [21]. In this work, the optimized chimera 
led to the expression of new powerful antigens, thus triggering an immune response against 
the tumor. This chimera was able to generate higher lymphocyte infiltration, decreasing tumor 
growth and increasing mice survival in a B-cell lymphoma tumor model [21].
The expression of new antigens is in some cases insufficient due to the immunosuppressive 
microenvironment. In fact, the expression of new antigens induces regulatory T-cell (Treg) 
infiltration indicating that the combination with other aptamer-based strategies would serve 
to optimize the antitumor immune responses. Signal transducer and activator of transcrip-
tion 3 (STAT-3)-targeted inhibition can be achieved using Toll-like receptor 9 (TLR9) natural 
ligands such as CpG. It has been demonstrated that this targeted inhibition triggers a strong 
antitumor immune response mediated by the activation of tumor-associated immune cells 
Aptamers as a Promising Therapeutic Tool for Cancer Immunotherapy
http://dx.doi.org/10.5772/66964
141
[80, 95]. In addition, STAT-3 is upregulated in immunosuppressive cells and favors CD4+ Treg 
expansion. Aptamer-based CTLA-4 delivery strategies have been demonstrated to target both 
CD4+ Tregs and CD8+ infiltrated lymphocytes [81]. CTLA-4 aptamer-based-targeting delivery 
of STAT-3 siRNA to T lymphocytes results in inhibition of tumor growth and of metastasis 
[81]. STAT-3 promotes tumor cell survival and proliferation in tumor cells, as well as invasion 
and immunosuppression [81]. This work shows an increase of CD8+ T-effector response in 
vivo thanks to the blockade of CTLA-4 in the first place and subsequently to STAT-3 silenc-
ing. STAT-3 inhibition provided a systemic antitumor response leading to inhibition of tumor 
growth in various cancer cell lines as well as metastasis [81].
mTOR is an intracellular mediator associated with the presence of immune-system shod-liv-
ing cells [3]. A strategy that demonstrated the agonistic 4-1BB optima coupled with an siRNA 
for a key factor of the mTOR complex 1(mTORC1) was called raptor [3]. This strategy resulted 
in mTORC1 downregulation in vitro, and its combination with an already established vac-
cination protocol promoted a protective immunity in a murine tumor model. This achieved 
antitumor response showed memory features with cytotoxic effect function [3].
Moreover, an RNA aptamer toward DEC205 has been recently published able to delivery in vitro 
deliver-specific cargoes for cross-presentation. DEC205 is a surface receptor expressed on CD8+α 
dendritic cells, which promotes antigen cross-presentation and the subsequent CD8+ activation. 
The use of this aptamer in vivo displayed strong T-cell-mediated tumor immunity [96].
Our research team has recently shown a new strategy to increase tumor immunogenicity by 
targeting the inhibition of FOXP3. We generated a CD28 aptamer chimera coupled with the 
already published FOXP3 transient inhibitory peptide P60 [82, 97]. This peptide is able to pen-
etrate into Tregs and inhibits its function [82]. Due to the absence of specificity of the P60 pep-
tide, we decided to couple it with one of our CD28 described aptamers and therefore target 
FOXP3 inhibition to CD28-expressing cells. This targeted inhibition counteracted Treg immu-
nosuppression activity while reducing the concentration hundreds of times up to 0.5 mictoM 
[82, 97]. A very similar antitumor effect in a colon carcinoma tumor model was achieved using 
625 pmol of the CD28-P60 chimera compared with 500 nmol of the P60 control [97].
3. Conclusion
Aptamers have gained a large spot among therapeutic agents [5] in several research fields. 
They have colonized experimental approaches for the treatment of several metabolic and vas-
cular diseases, and their preclinical use in cancer treatments has been widely used. Aptamers 
can be used to face the three major challenges that immunotherapy poses today [51]. To 
address the blockade of immunosuppressing signals, aptamers toward CTLA-4, PD1, TIM3, 
IL-10R, or IL-6 can be used. With the purpose of activating positive signals, agonistic aptam-
ers directed to trigger CD28, 4-1BB, OX40, or CD40 receptors can be utilized. In order to 
increase tumor immunogenicity, several aptamer-based strategies can be used, such as target-
ing the NMD inhibition to the tumor, STAT-3-targeted inhibition in TILs, or FOXP3-targeted 
inhibition in Tregs. Finally, it is to be noted that bi-specific aptamers such as 4-1BB-PSMA, 
4-1BB-VEGF, CD28-MRP1, or CD16α-c-MET can be utilized to direct the immune response 
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to the tumor site. To conclude, despite the youth of this emerging platform, aptamers might 
feasibly serve as a promising therapeutic tool for cancer immunotherapy.
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